Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors

Table 1 Clinicopathological features of 96 patients with gastrointestinal stromal tumor

	n	% of 96 GISTs
Age (yr, median age = 55 yr)
< 40	12	12.5
40-60	52	54.2
> 60	32	33.3
Sex
Male	57	59.4
Female	39	40.6
Site
Esophagus	3	3.1
Gastric	45	46.9
Intestine	37	38.5
EGIST	11	11.5
Tumor size (cm, median size = 7.0)
≤ 2	7	7.3
> 2 to ≤ 5	29	30.2
> 5 to ≤ 10	34	35.4
> 10	26	27.1
Mitotic rate (per 50 HPFs)
≤ 5	54	56.3
6 to 10	28	29.2
> 10	14	14.6
Risk of malignancy
High risk	45	46.9
Intermediate risk	24	25.0
Low risk	24	25.0
Very low risk	3	3.1

GISTs: Gastrointestinal stromal tumors; EGIST: Extra GIST; HPFs: High-power fields.